Skip to main content

FABHALTA was studied in both C5i-experienced (eculizumab and ravulizumab) and complement inhibitor–naive adults with PNH

Definitions
ARC, absolute reticulocyte count; bid, twice daily; C5i, C5 inhibitor; Ci, complement inhibitor; FACIT-Fatigue, Functional Assessment of Chronic Illness Therapy-Fatigue; Hb, hemoglobin; LDH, lactate dehydrogenase; MAVE, major adverse vascular event; PNH, paroxysmal nocturnal hemoglobinuria; RBC, red blood cell; ULN, upper limit of normal; WBC, white blood cell.

References
1. Fabhalta. Prescribing information. Novartis Pharmaceuticals Corp.
2. Data on file. Study CLNP023C12302 CSR. Novartis Pharmaceuticals Corp; 2022.
3. Data on file. Phase III APPLY-PNH and APPOINT-PNH Trials. Novartis Pharmaceuticals Corp; October 2023.
4. Data on file. Study CLNP023C12301 CSR. Novartis Pharmaceuticals Corp; 2022.
5. Data on file. Study CLNP023C12301 and Study CLNP023C12302 supporting analyses for USPI clinical efficacy section. Novartis Pharmaceuticals Corp; 2023.